Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and Ceribell also priced IPOs to join the public markets. The post Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M appeared first on MedCity News.

View Entire Post